Drug Profile
Cancer vaccine - InCytu
Alternative Names: CellariumLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator InCytu
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioma; Malignant melanoma
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Glioma in USA (Parenteral)
- 12 Sep 2023 Discontinued - Preclinical for Malignant melanoma in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Glioma in USA (Parenteral, Implant)